NCT00015483|Completed
Hematotoxic Effects of Particulate Exposure
Hematotoxic Effects of Benzene and Doxorubicin
Loading search results
Hematotoxic Effects of Benzene and Doxorubicin
Sponsor study identifier
observational
N/A
0 countries
N/A
Study Start
Not reported
Date not reportedPrimary Completion
Not reported
Date not reportedStudy Completion
Not reported
Date not reportedHematotoxicity is caused by a number of agents such as a benzene by-product called hydroquinone and the antitumor agent doxorubicin. This is a basic research study, conducted using normal human donors, of mechanisms involved in hematotoxicity and of the protective response of human hematopoietic progenitor cells to hematotoxic agents. Tumor necrosis factor exposure protects these cells from a subsequent exposure to hematotoxic agents. The alteration of gene expression in these cells caused by tumor necrosis factor is being studied. Additionally, the tumor necrosis factor-induced biochemical pathways involved in protection of human hematopoietic progenitor cells will be studied.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 20, 2001
Actual (reported)April 23, 2001
Actual (reported)Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
First Submitted
April 20, 2001
First Posted
April 23, 2001
Last Updated
September 4, 2006
Record last verified: 2006-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Monitoring HDR Brachytherapy for Cervical Cancer by Optic and Thermal Imaging